Activity

Gina McLane - October 24 VIEW RECORDING: https://fathom.video/share/r-PMos_zXxf1wj4BzJqmt7Mmx-zAiijz Challenges with endogenous analytes in control materials @ 0:00 Gina explained that the hospital lab needs control materials with endogenous analytes like hormones stripped out, as their assays measure these at very low levels (nanograms per deciliter) compared to typical drug testing. The blank matrices UTAK had provided previously had detectable levels of these endogenous analytes, which was not suitable. Gina discussed the need for either charcoal-stripped or synthetic serum matrices that are truly blank for these analytes. Exploring synthetic serum options @ 3:53 Nicole outlined UTAK's options for providing a suitable matrix - either diluting a human serum matrix to lower the endogenous levels, or using a synthetic serum matrix that would be expected to have zero levels of the target analytes. Gina expressed a preference for the synthetic serum approach, as dilutions can impact the matrix properties. They agreed to have UTAK send samples of their synthetic serum for Gina to evaluate. Reviewing previous quotes and cost considerations @ 8:17 Raleigh and Gina reviewed previous quotes UTAK had provided, including a very high-cost quote for a 60-analyte pain management panel that was not feasible for Gina's budget. Gina explained that she would need to pare down the analyte list and potentially have UTAK provide a single high-level control that Gina's lab could then dilute to create multiple QC levels, in order to keep costs manageable. Next steps and action items @ 17:59 Raleigh and Nicole agreed to provide Gina with information on the highest-cost analytes in the panel, so she could assess which ones to potentially remove. They also discussed following up on a previous order for xylosine controls that Gina was still waiting for. Overall, the group had a productive discussion and agreed on next steps to move the project forward.